Know Cancer

or
forgot password

Blood Samples to Evaluate Immune Response to Provenge® (Sipuleucel-T) inHormone Refractory Metastatic Prostate Cancer Patients


N/A
N/A
N/A
Not Enrolling
Both
Prostate Cancer, Immune Response to Provenge

Thank you

Trial Information

Blood Samples to Evaluate Immune Response to Provenge® (Sipuleucel-T) inHormone Refractory Metastatic Prostate Cancer Patients

Inclusion Criteria


In order for patients to receive treatment with Provenge® (Sipuleucel-T) at the Mary
Crowley clinic, patients must consent to the additional blood draws and be willing to come
into the clinic in adherence to the schedule of blood sample collections. Patients who do
not consent to these immune response blood samples will be unable to receive Provenge®
(Sipuleucel-T) at Mary Crowley but will be referred to a another physician and/or clinic
able to provide Provenge® (Sipuleucel-T).

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Authority:

United States: Mary Crowley Medical Research Center IRB

Study ID:

MC 10-11

NCT ID:

NCT01274572

Start Date:

January 2011

Completion Date:

Related Keywords:

  • Prostate Cancer
  • Immune Response to Provenge
  • Prostatic Neoplasms

Name

Location